# Dermatology and Skin Diseases

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/dermatology-and-skin-diseases/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on atopic dermatitis, exploring topics such as the role of filaggrin mutations, the skin microbiome, immune dysregulation, pruritus, and the use of dupilumab in treatment. It also delves into the impact of Staphylococcus aureus and the role of TSLP in allergic inflammation. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10837 |
| Works | 776 |

## Topic papers all

Showing 15 of 776.

- [Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis](https://scholariq.org/papers/common-loss-of-function-variants-of-the-epidermal-barrier-protein-filaggrin-are/)
- [Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003](https://scholariq.org/papers/revised-nomenclature-for-allergy-for-global-use-report-of-the-nomenclature/)
- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis](https://scholariq.org/papers/endogenous-antimicrobial-peptides-and-skin-infections-in-atopic-dermatitis/)
- [Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma](https://scholariq.org/papers/dupilumab-efficacy-and-safety-in-moderate-to-severe-uncontrolled-asthma/)
- [Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens](https://scholariq.org/papers/interleukin-22-mediates-early-host-defense-against-attaching-and-effacing/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/)
- [Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis](https://scholariq.org/papers/interleukin-22-a-th17-cytokine-mediates-il-23-induced-dermal-inflammation-and/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis-3/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis/)
- [Atopic Dermatitis](https://scholariq.org/papers/atopic-dermatitis-4/)
- [The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions](https://scholariq.org/papers/the-global-burden-of-skin-disease-in-2010-an-analysis-of-the-prevalence-and/)
- [Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients](https://scholariq.org/papers/fecal-microbiota-transplant-promotes-response-in-immunotherapy-refractory/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis-2/)
- [The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria](https://scholariq.org/papers/the-eaaci-ga2len-edf-wao-guideline-for-the-definition-classification-diagnosis-2/)

## Topic primary papers

Showing 15 of 448.

- [Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis](https://scholariq.org/papers/common-loss-of-function-variants-of-the-epidermal-barrier-protein-filaggrin-are/)
- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis-3/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis/)
- [Atopic Dermatitis](https://scholariq.org/papers/atopic-dermatitis-4/)
- [The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions](https://scholariq.org/papers/the-global-burden-of-skin-disease-in-2010-an-analysis-of-the-prevalence-and/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis-2/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [New insights into atopic dermatitis](https://scholariq.org/papers/new-insights-into-atopic-dermatitis/)
- [Guidelines of care for the management of atopic dermatitis](https://scholariq.org/papers/guidelines-of-care-for-the-management-of-atopic-dermatitis-2/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis..](https://scholariq.org/papers/the-u-k-working-party-s-diagnostic-criteria-for-atopic-dermatitis/)
- [Atopic dermatitis and the atopic march](https://scholariq.org/papers/atopic-dermatitis-and-the-atopic-march/)
- [Guidelines of care for the management of atopic dermatitis](https://scholariq.org/papers/guidelines-of-care-for-the-management-of-atopic-dermatitis-3/)
- [Filaggrin Mutations Associated with Skin and Allergic Diseases](https://scholariq.org/papers/filaggrin-mutations-associated-with-skin-and-allergic-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.